Ovarian Cancer Diagnostics Market Size, Share, & Trends Analysis Report By Diagnosis Type (Imaging, Blood Test), By Cancer Type (Epithelial Tumor, Stromal Cell Tumor), By End Use, By Region, And Segment Forecasts, 2019 - 2026

Published: Jul, 2019 | Pages: 100 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.

Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.

Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.

The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more

Further key findings from the report suggest:

• Incidence of ovarian cancer worldwide has been declining over the past decades

• Although ultrasound imaging is the fist-line of diagnosis, the technique cannot be used for staging the disease

• Computerized Tomography (CT) imaging is preferred for staging the disease

• CA125 remained the mainstay in blood test biomarkers in 2018

• HER2 and BRCA1/2 tests are expected to witness a rapid growth during the forecast period owing to the rising awareness of early diagnosis and genetic tests

• The ovarian cancer diagnostics market in Asia Pacific is expected to grow at a high rate during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources & third-party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global Ovarian Cancer Diagnostics Market Variables, Trends, & Scope
3.1. Ovarian Cancer Diagnostics Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of ovarian cancer
3.4.1.2. Novel approaches in ovarian cancer treatment
3.4.1.3. Technological advancements
3.4.1.4. Increased funding for cancer research
3.4.2. Market restraint analysis
3.4.2.1. High cost of diagnosis
3.4.2.2. Adverse effects
3.5. Ovarian Cancer Diagnostics Market Analysis Tools
3.5.1. Industry analysis - Porter's
3.5.1.1. Supplier Power: Low due to large number of suppliers
3.5.1.2. Buyer Power: High due to technological advancements
3.5.1.3. Substitution Threat: Moderate due to novel product launches
3.5.1.4. Threat from New Entrant: Moderate due to stringent regulatory policies
3.5.1.5. Competitive Rivalry: High due to increasing mergers & acquisitions by players
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Environmental landscape
3.5.2.3. Social landscape
3.5.2.4. Technology landscape
3.5.2.5. Legal landscape

Chapter 4. Ovarian Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Cancer Type Market Share Analysis, 2018 & 2026
4.3. Cancer Type Dashboard
4.4. Global Ovarian Cancer Diagnostics Market, by Cancer Type, 2015 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026
4.5.1. Epithelial tumor
4.5.1.1. Epithelial tumor market, 2015 - 2026 (USD Million)
4.5.2. Germ cell tumor
4.5.2.1. Germ cell tumor market, 2015 - 2026 (USD Million)
4.5.3. Stromal cell tumor
4.5.3.1. Stromal cell tumor market, 2015 - 2026 (USD Million)
4.5.4. Others
4.5.4.1. Others market, 2015 - 2026 (USD Million)

Chapter 5. Ovarian Cancer Diagnostics Market: Diagnosis Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Diagnosis Type Market Share Analysis, 2018 & 2026
5.3. Diagnosis Type Dashboard
5.4. Global Ovarian Cancer Diagnostics Market, by Diagnosis Type, 2015 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026
5.5.1. Imaging
5.5.1.1. Imaging market, 2015 - 2026 (USD Million)
5.5.2. Blood test
5.5.2.1. Blood test, 2015 - 2026 (USD Million)
5.5.3. Biopsy
5.5.3.1. Biopsy market, 2015 - 2026 (USD Million)
5.5.4. Others
5.5.4.1. Others market, 2015 - 2026 (USD Million)

Chapter 6. Ovarian Cancer Diagnostics Market: End-use Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. End-use Market Share Analysis, 2018 & 2026
6.3. End-use Dashboard
6.4. Global Ovarian Cancer Diagnostics Market, by End Use, 2015 to 2026
6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026
6.5.1. Hospital laboratories
6.5.1.1. Hospital laboratories market, 2015 - 2026 (USD Million)
6.5.2. Cancer diagnostic centers
6.5.2.1. Cancer diagnostic centers, 2015 - 2026 (USD Million)
6.5.3. Research institutes
6.5.3.1. Research institutes, 2015 - 2026 (USD Million)
6.5.4. Others
6.5.4.1. Others, 2015 - 2026 (USD Million)

Chapter 7. Ovarian Cancer Diagnostics Market: Regional Estimates & Trend analysis
7.1. Regional Market Snapshot
7.2. Regional Market Share and Leading Players, 2018
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
7.4.1. North America
7.4.1.1. North America ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.1.2. U.S.
7.4.1.2.1. U.S. ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.1.3. Canada
7.4.1.3.1. Canada ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.2. Europe
7.4.2.1. Europe ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.2.2. U.K.
7.4.2.2.1. U.K. ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.2.3. Germany
7.4.2.3.1. Germany ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.2.4. Spain
7.4.2.4.1. Spain ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.2.5. France
7.4.2.5.1. France ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.2.6. Italy
7.4.2.6.1. Italy ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.3. Asia Pacific
7.4.3.1. Asia Pacific ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.3.2. China
7.4.3.2.1. China ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.3.3. Japan
7.4.3.3.1. Japan ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.3.4. India
7.4.3.4.1. India ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.3.5. South Korea
7.4.3.5.1. South Korea ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.3.6. Australia
7.4.3.6.1. Australia ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.4. Latin America
7.4.4.1. Latin America ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.4.2. Brazil
7.4.4.2.1. Brazil ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.4.3. Mexico
7.4.4.3.1. Mexico ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.4.4. Argentina
7.4.4.4.1. Argentina ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.5. Middle East and Africa
7.4.5.1. Middle East and Africa ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.5.2. South Africa
7.4.5.2.1. South Africa ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.5.3. Saudi Arabia
7.4.5.3.1. Saudi Arabia ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
7.4.5.4. UAE
7.4.5.4.1. UAE ovarian cancer diagnostics market, 2015 - 2026 (USD Million)

Chapter 8. Company Profiles
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.3. Public Companies
8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
8.3.2. Competitive dashboard analysis
8.3.3. Market differentiators
8.4. Private Companies
8.5. Company Profiles
8.5.1. F. Hoffmann-La Roche AG
8.5.1.1. Company overview
8.5.1.2. Financial performance
8.5.1.3. Product benchmarking
8.5.1.4. Strategic initiatives
8.5.2. Johnson & Johnson Services, Inc.
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product benchmarking
8.5.2.4. Strategic initiatives
8.5.3. GlaxoSmithKline Plc
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product benchmarking
8.5.3.4. Strategic initiatives
8.5.4. AstraZeneca Plc
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Siemens Healthcare GmbH
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Abbott
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product benchmarking
8.5.6.4. Strategic initiatives
8.5.7. Thermo Fisher Scientific
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bio-Rad Laboratories, Inc.
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Quest Diagnostics Incorporated.
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product benchmarking
8.5.9.4. Strategic initiatives

List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 3 North America ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 4 North America ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 5 U.S. ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 6 U.S. ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 7 U.S. ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 8 Canada ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 9 Canada ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 10 Canada ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 11 Europe ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 12 Europe ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 13 Europe ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 14 U.K. ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 15 U.K. ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 16 U.K. ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 17 Germany ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 18 Germany ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 19 Germany ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 20 France ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 21 France ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 22 France ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 23 Italy ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 24 Italy ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 25 Italy ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 26 Spain ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 27 Spain ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 28 Spain ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 29 Asia Pacific ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 30 Asia Pacific ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 31 Asia Pacific ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 32 Japan ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 33 Japan ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 34 Japan ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 35 China ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 36 China ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 37 China ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 38 India ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 39 India ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 40 India ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 41 South Korea ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 42 South Korea ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 43 South Korea ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 44 Australia ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 45 Australia ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 46 Australia ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 47 Latin America ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 48 Latin America ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 49 Latin America ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 50 Brazil ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 51 Brazil ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 52 Brazil ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 53 Mexico ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 54 Mexico ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 55 Mexico ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 56 Argentina ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 57 Argentina ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 58 Argentina ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 59 MEA ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 60 MEA ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 61 MEA ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 62 South Africa ovarian n cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 63 South Africa ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 64 South Africa ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 65 Saudi Arabia ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 66 Saudi Arabia ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 67 Saudi Arabia ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)
TABLE 68 UAE ovarian cancer diagnostics market, by cancer type, 2015 - 2026 (USD Million)
TABLE 69 UAE ovarian cancer diagnostics market, by diagnosis type, 2015 - 2026 (USD Million)
TABLE 70 UAE ovarian cancer diagnostics market, by end use, 2015 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global ovarian cancer diagnostics market- Key market driver analysis
FIG. 7 Global ovarian cancer diagnostics market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global ovarian cancer diagnostics market - Porter's analysis
FIG. 10 Global ovarian cancer diagnostics market - PESTEL analysis
FIG. 11 Global ovarian cancer diagnostics market cancer type outlook key takeaways
FIG. 12 Global ovarian cancer diagnostics market: Cancer type movement analysis
FIG. 13 Epithelial tumor market estimates, 2015 - 2026 (USD Million)
FIG. 14 Germ cell tumor market estimates, 2015 - 2026 (USD Million)
FIG. 15 Stromal cell tumor market estimates, 2015 - 2026 (USD Million)
FIG. 16 Others market estimates, 2015 - 2026 (USD Million)
FIG. 17 Global ovarian cancer diagnostics market diagnosis type outlook key takeaways
FIG. 18 Global ovarian cancer diagnostics market: Diagnosis type movement analysis
FIG. 19 Imaging market estimates, 2015 - 2026 (USD Million)
FIG. 20 Blood test market estimates, 2015 - 2026 (USD Million)
FIG. 21 Biopsy market estimates, 2015 - 2026 (USD Million)
FIG. 22 Others market estimates, 2015 - 2026 (USD Million)
FIG. 23 Global ovarian cancer diagnostics market end use outlook key takeaways
FIG. 24 Global ovarian cancer diagnostics market: End use movement analysis
FIG. 25 Hospital laboratories market estimates, 2015 - 2026 (USD Million)
FIG. 26 Cancer diagnostics centers market estimates, 2015 - 2026 (USD Million)
FIG. 27 Research institutes market estimates, 2015 - 2026 (USD Million)
FIG. 28 Others market estimates, 2015 - 2026 (USD Million)
FIG. 29 Regional marketplace: Key takeaways
FIG. 30 Global ovarian cancer diagnostics market: Regional movement analysis
FIG. 31 North America ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 32 U.S. ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 33 Canada ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 34 Europe ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 35 U.K. ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 36 Germany ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 37 France ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 38 Spain ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 39 Italy ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 40 Asia Pacific ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 41 Japan ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 42 China ovarian cancer diagnostics s market, 2015 - 2026 (USD Million)
FIG. 43 India ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 44 South Korea ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 45 Australia ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 46 Latin America ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 47 Brazil ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 48 Mexico ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 49 Argentina ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 50 MEA ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 51 South Africa ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 52 Saudi Arabia ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 53 UAE ovarian cancer diagnostics market, 2015 - 2026 (USD Million)
FIG. 54 Strategy framework